KYORIN Pharmaceutical (4569) Q1 2027 earnings summary

Executive summary

• Net sales for FY2026 1Q decreased by 1.9% year-over-year to ¥29,654 million, mainly due to lower sales of new drugs in Japan and overseas, despite growth in Beova and generic drugs.

• Operating profit dropped 59.3% year-over-year to ¥964 million, impacted by higher R&D expenses and increased SG&A costs.

• Profit attributable to owners of parent fell 60.8% year-over-year to ¥824 million.

• Comprehensive income fell sharply by 98.5% to ¥30 million for the quarter.

Financial highlights

• Net sales: ¥29,654 million (down ¥575 million year-over-year).

• Operating profit: ¥964 million (down ¥1,404 million year-over-year).

• Ordinary profit: ¥1,241 million (down ¥1,382 million year-over-year).

• Basic earnings per share for the quarter were ¥14.35, down from ¥36.57 a year earlier.

• Equity ratio improved to 74.4% from 72.9% at the end of the previous fiscal year.

Outlook and guidance

• FY2026 interim and full-year forecasts remain unchanged: net sales forecast at ¥57,800 million (interim) and ¥121,800 million (full year).

• Full-year profit attributable to owners of parent is projected at ¥1,500 million, down 56.5% year-over-year.

• Earnings per share for the full year are forecast at ¥26.11.

• Annual dividend plan maintained at ¥25 per share.